Biodexa Pharmaceticals (BDRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biodexa Pharmaceticals (BDRX) has a cash flow conversion efficiency ratio of -0.289x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.30 Million) by net assets ($11.44 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Biodexa Pharmaceticals - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Biodexa Pharmaceticals's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Biodexa Pharmaceticals for a breakdown of total debt and financial obligations.
Biodexa Pharmaceticals Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biodexa Pharmaceticals ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cyber Security 1 AB
ST:CYB1
|
0.681x |
|
Michelmersh Brick Holdings Plc
LSE:MBH
|
0.020x |
|
Dixie Gold Inc
V:DG
|
-0.079x |
|
IG Design Group plc
LSE:IGR
|
-0.368x |
|
Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG
XETRA:EFF
|
0.000x |
|
ExpreS2ion Biotech Holding AB
ST:EXPRS2
|
0.019x |
|
CAT STRATEGIC MET.
F:8CHA
|
-0.016x |
|
WICKET GAMING AB
F:7Q4
|
N/A |
Annual Cash Flow Conversion Efficiency for Biodexa Pharmaceticals (2012–2024)
The table below shows the annual cash flow conversion efficiency of Biodexa Pharmaceticals from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see BDRX market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $8.32 Million | $-12.26 Million | -1.473x | -0.97% |
| 2023-12-31 | $4.68 Million | $-6.83 Million | -1.459x | +34.54% |
| 2022-12-31 | $3.16 Million | $-7.05 Million | -2.229x | -287.79% |
| 2021-12-31 | $10.45 Million | $-6.01 Million | -0.575x | +58.48% |
| 2020-12-31 | $6.72 Million | $-9.30 Million | -1.384x | -317.29% |
| 2019-12-31 | $19.56 Million | $-6.49 Million | -0.332x | +58.25% |
| 2018-12-31 | $16.92 Million | $-13.45 Million | -0.795x | -112.75% |
| 2017-12-31 | $34.68 Million | $-12.95 Million | -0.374x | -30.52% |
| 2016-12-31 | $45.72 Million | $-13.09 Million | -0.286x | -8.03% |
| 2015-12-31 | $46.89 Million | $-12.42 Million | -0.265x | -103.91% |
| 2014-12-31 | $41.99 Million | $-5.46 Million | -0.130x | +97.77% |
| 2013-12-31 | $760.00K | $-4.44 Million | -5.837x | -1023.99% |
| 2012-12-31 | $-5.09 Million | $-3.22 Million | 0.632x | -- |
About Biodexa Pharmaceticals
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatm… Read more